Acid reflux medicine is essential for treating those nasty and painful symptoms associated with the condition but before you get the medicine you need, it’s time to get diagnosed. This can only be done by a doctor so it’s time to make that appointment!
After this appointment has been made and you know that your symptoms are definitely caused by acid reflux you can then go on to choose the right treatment for you and thankfully, there are many options available.
First of all, one of the first things that you will need to work out is whether or not you would benefit from over the counter acid reflux medicine or prescription medicine. There are both advantages and disadvantages to both of these options and some may be more expensive than others but incidentally it is down to personal preference.
The doctor may advise you to go with one treatment and it would be better to try this option first while trying to incorporate a few lifestyle changes to see if that makes a difference.
Either way, whether you go for the over counter acid reflux medicine or the prescription ones that are advised by your doctor, they are both designed for short term use and should not be used over longer periods of time.
Vonseca® is the first full range Generic of Vonoprazan In Egypt
As per its commitment to offer the latest treatment for the Egyptian’s patients., in Jan 2022 Zeta Pharma was the first Egyptian pharmaceutical company to introduce two concentrations of 10mg and 20 mg of vonoprazan in the Egyptian market through its brand Vonseca.®
? is a first-in-class potassium-competitive acid blocker. It was approved in the Japanese market in February 2015.
Vonoprazan is used in form of the fumarate for the treatment of gastroduodenal ulcer (including some drug-induced peptic ulcers) and reflux esophagitis, and can be combined with antibiotics for the eradication of Helicobacter pylori.
The (?) has approved 2 ?-based medications for the treatment of Helicobacter pylori (H. pylori) infection.
The approval of ? treatment regimens offers physicians and patients 2 therapeutic options that showed superior eradication rates compared to proton pump inhibitor-based (PPI) lansoprazole triple therapy in the overall patient population in a pivotal trial.
? belongs to a class of products known as PCAB, or potassium-competitive acid blockers. By blocking the potassium-binding site of gastric hydrogen potassium ATPase (also known as the proton pump), which is the enzyme largely responsible for acidification of the stomach, it’s designed to overcome many of the perceived weaknesses of traditional proton pump inhibitor therapy.
If you need any kind of information on this article related topic click here: Vonaspire